Get the Stockscreener App
168.22
2.40%
-4.13
After Hours:
165.00
-3.22
-1.91%
Praxis Precision Medicines Inc stock is traded at $168.22, with a volume of 514.79K.
It is down -2.40% in the last 24 hours and up +223.25% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
See More
Previous Close:
$172.35
Open:
$170.17
24h Volume:
514.79K
Relative Volume:
0.65
Market Cap:
$3.54B
Revenue:
$1.77M
Net Income/Loss:
$-123.74M
P/E Ratio:
-18.34
EPS:
-9.17
Net Cash Flow:
$-95.21M
1W Performance:
-15.37%
1M Performance:
+223.25%
6M Performance:
+341.64%
1Y Performance:
+123.25%
1-Day Range:
$159.74
$172.00
1-Week Range:
$154.45
$186.72
52-Week Range:
$26.70
$206.71
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Compare PRAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
168.22 | 4.31B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-03-25 | Reiterated | H.C. Wainwright | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Aug-05-24 | Initiated | Oppenheimer | Outperform |
| Jun-24-24 | Initiated | Needham | Buy |
| Jun-18-24 | Initiated | Guggenheim | Buy |
| May-01-24 | Initiated | Robert W. Baird | Outperform |
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
How analysts rate Praxis Precision Medicines Inc. stock todayWeekly Stock Recap & Target Return Focused Picks - newser.com
Published on: 2025-11-08 04:02:56 - newser.com
Using fundamentals and technicals on Praxis Precision Medicines Inc.Weekly Profit Recap & Daily Volume Surge Signals - newser.com
Is Praxis Precision Medicines Inc. stock a contrarian buy2025 Valuation Update & Daily Chart Pattern Signals - newser.com
Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $270 From $280, Maintains Buy Rating - MarketScreener
Does Praxis Precision Medicines Inc. qualify in momentum factor screeningTrade Risk Report & Risk Adjusted Buy and Sell Alerts - newser.com
Wedbush Maintains Praxis Precision Medicines (PRAX) Underperform Recommendation - Nasdaq
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline - Investing.com Canada
Guggenheim raises Praxis Precision Medicines stock price target on CNS pipeline By Investing.com - Investing.com South Africa
PRAX: Wedbush Raises Price Target While Maintaining Underperform Rating | PRAX Stock News - GuruFocus
Praxis Precision announces inducement grants under Nasdaq lsiting rule - TipRanks
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines (NASDAQ: PRAX) grants 6,876 RSUs under 2024 Inducement Plan - Stock Titan
Is a relief rally coming for Praxis Precision Medicines Inc. holders2025 Market WrapUp & AI Based Buy and Sell Signals - newser.com
How institutional buying supports Praxis Precision Medicines Inc. stock2025 Volume Leaders & Real-Time Volume Analysis - newser.com
Can Praxis Precision Medicines Inc. stock deliver surprise earnings beat2025 Retail Activity & Real-Time Stock Entry Alerts - newser.com
What valuation multiples suggest for Praxis Precision Medicines Inc. stockWeekly Stock Report & Consistent Profit Trade Alerts - newser.com
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines Reports Q3 2025 Financial Results - TipRanks
Compounding Losses Challenge Bullish Profit Growth Narratives at Praxis Precision Medicines (PRAX) - Yahoo Finance
What institutional flow reveals about Praxis Precision Medicines Inc.Earnings Summary Report & Daily Stock Momentum Reports - newser.com
Praxis Precision Medicine’s Soaring Success: What Will Happen Next? - timothysykes.com
Praxis Precision Medicines to Participate in Upcoming Investor Conferences - The Manila Times
Using Python tools to backtest Praxis Precision Medicines Inc. strategiesJuly 2025 Closing Moves & Technical Pattern Based Buy Signals - newser.com
Praxis (NASDAQ: PRAX) to join Truist, HC Wainwright, Guggenheim, Jefferies; webcasts - Stock Titan
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results - Investing News Network
Praxis Precision Medicines Bets On Big R&D As Losses Grow - Finimize
Can Praxis Precision Medicines Inc. stock deliver consistent earnings growth2025 Price Action Summary & Technical Pattern Alert System - fcp.pa.gov.br
Praxis Precision Medicines Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Praxis Precision Medicines Q3 Net Loss Widens - MarketScreener
PRAX Achieves Milestone with Successful Phase 3 Program - GuruFocus
Praxis Precision Medicines Q3 net loss widens - MarketScreener
Praxis Precision Medicines, Inc. SEC 10-Q Report - TradingView
[8-K] Praxis Precision Medicines, Inc. Reports Material Event | PRAX SEC FilingForm 8-K - Stock Titan
[10-Q] Praxis Precision Medicines, Inc. Quarterly Earnings Report | PRAX SEC FilingForm 10-Q - Stock Titan
Praxis Gets FDA Alignment on Relutrigine Program for Rare Pediatric Epilepsies - MarketScreener
Praxis Precision Medicines (NASDAQ:PRAX) Shares Gap DownHere's Why - MarketBeat
Praxis speeds up R&D plans for seizure therapy (PRAX:NASDAQ) - Seeking Alpha
PRAX Secures FDA Alignment on Relutrigine Program - GuruFocus
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback - The Manila Times
Praxis (NASDAQ: PRAX) Q4 2025 interim may back 2026 relutrigine NDA in SCN2A & SCN8A - Stock Titan
Published on: 2025-11-04 05:07:36 - newser.com
Published on: 2025-11-04 03:14:53 - newser.com
Published on: 2025-11-06 05:24:24 - newser.com
How Praxis Precision Medicines Inc. stock valuations compare to rivalsDollar Strength & Growth Focused Investment Plans - newser.com
Oppenheimer Lifts Price Target for Praxis Medicines (PRAX), Keeps Outperform Rating - MSN
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Praxis Precision Medicines Inc Stock (PRAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Option Exercise |
56.94 |
7,583 |
431,776 |
18,540 |
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):